FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models - Concepedia

Concepedia

Publication | Closed Access

FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models

42

Citations

22

References

2017

Year

Cristina Corno, Simone Stucchi, Michelandrea De Cesare, Nives Carenini, Serena Stamatakos, Emilio Ciusani, Lucia Minoli, Eugenio Scanziani, Christian Argueta, Yosef Landesman,

Biochemical Pharmacology

Foxo-1 ContributesMedicineOncogenic AgentGynecologyPathologyCancer BiologyTumor SuppressorCancer TreatmentOncologyXpo1 Inhibitor SelinexorTumor BiologyOvarian Cancer

References

	Year	Citations

Page 1

Page 1